ADMA Biologics(ADMA)

Search documents
Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know
ZACKS· 2024-07-31 22:51
Group 1 - Adma Biologics (ADMA) stock closed at $12.28, with a daily increase of +0.82%, underperforming the S&P 500's gain of 1.08% [1] - The stock has increased by 6.84% over the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's decline of 0.44% [1] - Upcoming earnings report is projected to show earnings of $0.08 per share, reflecting a year-over-year growth of 500%, with revenue expected at $87.03 million, up 44.75% from the previous year [1] Group 2 - Recent analyst estimate changes for Adma Biologics indicate a positive outlook, with no change in the Zacks Consensus EPS estimate over the past month [2] - Adma Biologics currently holds a Zacks Rank of 1 (Strong Buy), which has historically yielded an average annual return of +25% since 1988 [2] Group 3 - Adma Biologics is trading at a Forward P/E ratio of 34.8, which is higher than the industry average of 24.56, suggesting a premium valuation [3] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 86, placing it in the top 35% of over 250 industries [3]
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Seeking Alpha· 2024-07-27 12:29
bymuratdeniz ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived products for infectious diseases. However, ADMA’s market mostly focuses on immune-compromised patients. The company’s IP portfolio centers around three FDA-approved medications: Asceniv, Bivigam, and Nabi-HB. ADMA’s revenue streams primarily come from their FDA-approved products, with additional income from patented immunotechnology and contract development and manufacturing organization [CDMO] se ...
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
ZACKS· 2024-07-22 15:36
We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s (ADMA) portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.Factors to NoteADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, namely – Bivigam (to ...
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
ZACKS· 2024-07-18 22:56
Adma Biologics (ADMA) closed the most recent trading day at $13.05, moving -1.81% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.78% for the day. On the other hand, the Dow registered a loss of 1.29%, and the technology-centric Nasdaq decreased by 0.7%.The infectious disease drug developer's shares have seen an increase of 25.14% over the last month, surpassing the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%.Market participants will be ...
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Investor Place· 2024-07-13 13:00
Finding millionaire-making stocks is not easy. While we can’t tell the future, we can do the next best thing: think forward, gauge a company’s room for growth, and determine how it intends to reach the next level. Here lies the beauty of mid-cap stocks, a market cap category sometimes overlooked in favor of large and mega caps. For the uninitiated, mid-cap stocks trade with a market cap between $2 billion and $10 billion. Some consider it the sweet spot between growth potential and stability because the bus ...
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
ZACKS· 2024-07-09 14:41
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adma Biologics (ADMA) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adma Biologics is one of 1026 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sect ...
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
ZACKS· 2024-06-27 14:35
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently ha ...
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
ZACKS· 2024-06-26 22:55
Company Overview - Adma Biologics (ADMA) stock closed at $10.84, reflecting a -1.54% change from the previous day, underperforming compared to the S&P 500's 0.16% gain [1] - The stock has increased by 15.77% over the past month, outperforming the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% [1] Upcoming Earnings - The upcoming earnings release is highly anticipated, with an expected EPS of $0.08, indicating a 500% growth year-over-year [1] - Revenue is projected to be $87.03 million, representing a 44.75% increase compared to the same quarter last year [1] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important, as they reflect short-term business trends and analysts' confidence in the company's performance [2] - The Zacks Consensus EPS estimate has remained unchanged over the past month, with Adma Biologics holding a Zacks Rank of 3 (Hold) [2] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 31.46, which is a premium compared to the industry's average Forward P/E of 21.61 [3] - The Medical - Biomedical and Genetics industry has a Zacks Industry Rank of 90, placing it in the top 36% of over 250 industries [3]
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
ZACKS· 2024-06-20 22:55
Adma Biologics (ADMA) closed the latest trading day at $10.71, indicating a +0.85% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.25%. Elsewhere, the Dow saw an upswing of 0.77%, while the tech-heavy Nasdaq depreciated by 0.79%.Coming into today, shares of the infectious disease drug developer had gained 10.28% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%.Analysts and investors alike will be ...
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
ZACKS· 2024-06-11 14:30
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average br ...